Navigation Links
Pieris Raises EUR 25 M (US$ 38 M) in Series B Financing Round
Date:3/27/2008

r. Optimised for extended serum half-life, PRS-050 exhibits comparable binding and functional in vitro activity to approved VEGF antagonists. Potent inhibition of VEGF-induced enhanced vascular permeability and angiogenesis, as well as anti-tumour activity, have already been demonstrated for PRS-050 in various well-validated in vivo preclinical studies.

As a next generation VEGF antagonist, PRS-050 exploits several favourable characteristics of Anticalins(R), including compact protein structure, high intrinsic stability, broad formulation flexibility and small molecular size with the potential to penetrate neovascularized tumour tissue more effectively. PRS-050 is currently being prepared for a Phase I study in patients with advanced malignancies.

Further information on Pieris AG is available at http://www.pieris-ag.com

Anticalin(R) and Duocalin(R) are registered trademarks of Pieris AG.

About OrbiMed Advisors, LLC

OrbiMed is a preeminent asset management firm focused on the global health sciences industry, with over $6 billion in assets under management across a family of venture capital funds, hedge funds and other investment vehicles. OrbiMed's investment advisory activities were founded in 1989 by Samuel D. Isaly, with a vision to invest across the spectrum of healthcare companies from small privately-held firms to large multinational companies.

OrbiMed's investment team includes over 20 experienced professionals with backgrounds in science, medicine, finance and law. OrbiMed's professionals work together in a collaborative, team-oriented approach. OrbiMed seeks to be the capital provider of choice for life sciences companies pursuing growth and new opportunities. Where appropriate, particularly within its venture capital activities, OrbiMed supports its invested companies in achieving strategic, financial and operational objectives via participation at the Board of Di
'/>"/>

SOURCE Pieris AG
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Pieris Validates the Use of Anticalins(R) as Ophthalmologic Biotherapeutics
2. Moodys Raises Rating for Gerresheimer
3. SleepQuest Raises Awareness of Sleep Disorders
4. Arthrosurface Raises $4 Million of Preferred Equity Financing
5. Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimers Treatments
6. Skystar Bio-Pharmaceutical Raises 2007 Revenue Guidance to $15.8 Million
7. Circassia Raises GBP11 Million ($21.8 Million) in Oversubscribed Second Round Funding
8. Primera Biosystems Raises $21 Million in Series B Private Round
9. Cellectar, Inc. Raises $13 Million in Private Offering
10. Follica Raises $5.5 M To Advance New Treatment for Androgenetic Alopecia Into the Clinic
11. Anesiva Raises $45 Million in Common Stock Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Salt Lake City, Utah (PRWEB) August 27, 2014 ... new construction that will expand its current Salt Lake ... operations currently underway outside of Utah to ultimately create ... the next 20 years. , “Utah is home ... many of whom can be credited with Varian’s success ...
(Date:8/27/2014)... Green & Grow Inc. (GGI) has raised an ... Otter Capital as a significant new partner. Otter Capital’s ... Agriplier™ technology, building on recent compelling field trial results ... meeting, we have been impressed with Otter Capital’s knowledge ... Sobba, President and CEO of GGI. “We look forward ...
(Date:8/27/2014)... Aug. 27, 2014 Rhythm, a biopharmaceutical company ... deficiencies that result in metabolic disorders, announced today that ... with the U.S. Securities and Exchange Commission (SEC) relating ... its common stock. The number of shares to be ... not yet been determined. Citigroup and Cowen ...
(Date:8/27/2014)... In 2013, Lawrence Livermore ... National Security LLC (LLNS), was awarded more ... state-of-the-art laser system for the European Union's Extreme ... in the Czech Republic. , When commissioned to ... the " High repetition-rate Advanced Petawatt Laser System ...
Breaking Biology Technology:Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 2Varian Medical Systems Groundbreaking on Facility Expansion Triggers Influx of New Jobs to Salt Lake 3Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3Rhythm Files Registration Statement for Proposed Initial Public Offering 2LLNL Synchs up with ELI Beamlines on Timing System 2LLNL Synchs up with ELI Beamlines on Timing System 3
... 7, 2011 Vaxart, Inc., a San Francisco biotechnology company ... I clinical trial. This is the first clinical study evaluating ... The trial site is in the United States. ... is demonstrated with one vaccine, we can expect that later ...
... DuPont (NYSE: DD ) Chair and ... JPMorgan Diversified Industries Conference to expect attractive long-term growth ... in attractive areas, broad-based growth, especially in developing markets, ... DuPont,s 2011 earnings per share (EPS) outlook in the ...
... Systems International (OTCBB: IFRS) is pleased to announce that its ... NatuRx™ HIV/AIDS treatment and will push forward with clinical trials ... pilot study with two HIV/AIDS patients this week which also ... AIDS victims on June 5th, 1981. "The results ...
Cached Biology Technology:Vaxart Begins First Oral Vaccine Clinical Trial 2DuPont Chair & CEO: Delivering Innovative Solutions and Long-term Growth 2DuPont Chair & CEO: Delivering Innovative Solutions and Long-term Growth 3Infrared Systems International's Subsidiary, AquaLiv, Inc., Strives to Be a Game Changer in Fight Against HIV/AIDS 2Infrared Systems International's Subsidiary, AquaLiv, Inc., Strives to Be a Game Changer in Fight Against HIV/AIDS 3
(Date:8/27/2014)... The mechanical force that a single fungal cell or ... small, but it plays a heavy role in setting up ... fact, it may not be too much of a stretch ... without the ability to respond to the touch of beneficial ... a professor of agronomy at the University of Wisconsin-Madison. ...
(Date:8/27/2014)... 27, 2014  WaferGen Bio-systems, Inc. (NASDAQ: WGBS) today ... public offering of units of common stock and warrants ... proceeds of $20 million, prior to deducting underwriting discounts ... The shares and warrants are immediately separable and will ... in the offering consists of 2,000 shares of common ...
(Date:8/27/2014)... short-faced bears, giant ground sloths, saber-toothed cats and American ... ago at the end of the Pleistocene period. The ... by scientists who, until recently, could only speculate as ... Santa Barbara,s James Kennett, professor emeritus in the Department ... Earth played a major role in the extinction. Their ...
Breaking Biology News(10 mins):A touching story: The ancient conversation between plants, fungi and bacteria 2A touching story: The ancient conversation between plants, fungi and bacteria 3WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 2WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 3Nanodiamonds are forever 2Nanodiamonds are forever 3
... Registration is now open for Disease Models & ... Mechanisms. This one-day Symposium will ... and disease processes at the cellular and whole-organism ... be used to address this issue. It is ...
... flower, created by the union of two foreign plant species, ... Genetic changes in this attractive yellow-flowered hybrid have allowed it to ... new species that has originated in the wild in the last ... to have originated in this way, yet only a handful of ...
... A San Francisco State University biologist has released the ... bee populations and has found low numbers of bees in ... habitat loss is one of the primary reasons for sharp ... Now the researcher plans to add to her data ...
Cached Biology News:Rare glimpse into the origin of species 2SF State researcher releases first results from nationwide bee count 2SF State researcher releases first results from nationwide bee count 3
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. ID clarifier: ...
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. ID clarifier: ...
ID clarifier: With ethidium bromide (50 μg/ml)...
... in DMEM and harvested at the log phase ... antigens in their native forms, cells were fixed ... a 12-well (5 mm) adhesive coated slide, with ... attachment and to minimize background staining. Each ...
Biology Products: